{"title":"COVID-19疫苗接种后的施尼茨勒综合征","authors":"Mizuki Asako, H. Matsunaga, K. Oka, S. Ueda","doi":"10.2169/internalmedicine.9598-22","DOIUrl":null,"url":null,"abstract":"An 86-year-old Japanese woman was referred for an examination of leukocytosis and diagnosed with Waldenström macroglobulinemia. She was asymptomatic and remained stable during follow-up without treatment. The day after receiving her first COVID-19 vaccination (Pfizer-BioNTech), she developed urticarial exanthema on her limbs. Although the rash improved with topical steroids, it worsened the day after she received the second vaccination; bone pain, general fatigue, and leukocytosis (white blood cell count: 11,600/ μL) also developed. A skin biopsy showed perivascular and interstitial neutrophil infiltrate with leukocytoclasia (Picture A, B), and definite Schnitzler syndrome was diagnosed according to the Strasbourg criteria (1). She rapidly responded to low-dose prednisolone (10 mg/day), and the skin rash and systemic symptoms resolved. Schnitzler syndrome is autoinflammatory and characterized by urticarial rash and immunoglobulin M monoclonal gammopathy. Lymphoproliferative disorders feature immune dysregulation that often results in autoimmune disease (2). In patients with lymphoproliferative disorders, physicians should pay careful attention to immune complications after COVID-19 vaccination.","PeriodicalId":77259,"journal":{"name":"Medicina interna (Bucharest, Romania : 1991)","volume":"46 3","pages":"2397 - 2397"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Schnitzler Syndrome after COVID-19 Vaccination\",\"authors\":\"Mizuki Asako, H. Matsunaga, K. Oka, S. Ueda\",\"doi\":\"10.2169/internalmedicine.9598-22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"An 86-year-old Japanese woman was referred for an examination of leukocytosis and diagnosed with Waldenström macroglobulinemia. She was asymptomatic and remained stable during follow-up without treatment. The day after receiving her first COVID-19 vaccination (Pfizer-BioNTech), she developed urticarial exanthema on her limbs. Although the rash improved with topical steroids, it worsened the day after she received the second vaccination; bone pain, general fatigue, and leukocytosis (white blood cell count: 11,600/ μL) also developed. A skin biopsy showed perivascular and interstitial neutrophil infiltrate with leukocytoclasia (Picture A, B), and definite Schnitzler syndrome was diagnosed according to the Strasbourg criteria (1). She rapidly responded to low-dose prednisolone (10 mg/day), and the skin rash and systemic symptoms resolved. Schnitzler syndrome is autoinflammatory and characterized by urticarial rash and immunoglobulin M monoclonal gammopathy. Lymphoproliferative disorders feature immune dysregulation that often results in autoimmune disease (2). In patients with lymphoproliferative disorders, physicians should pay careful attention to immune complications after COVID-19 vaccination.\",\"PeriodicalId\":77259,\"journal\":{\"name\":\"Medicina interna (Bucharest, Romania : 1991)\",\"volume\":\"46 3\",\"pages\":\"2397 - 2397\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicina interna (Bucharest, Romania : 1991)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2169/internalmedicine.9598-22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina interna (Bucharest, Romania : 1991)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2169/internalmedicine.9598-22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
An 86-year-old Japanese woman was referred for an examination of leukocytosis and diagnosed with Waldenström macroglobulinemia. She was asymptomatic and remained stable during follow-up without treatment. The day after receiving her first COVID-19 vaccination (Pfizer-BioNTech), she developed urticarial exanthema on her limbs. Although the rash improved with topical steroids, it worsened the day after she received the second vaccination; bone pain, general fatigue, and leukocytosis (white blood cell count: 11,600/ μL) also developed. A skin biopsy showed perivascular and interstitial neutrophil infiltrate with leukocytoclasia (Picture A, B), and definite Schnitzler syndrome was diagnosed according to the Strasbourg criteria (1). She rapidly responded to low-dose prednisolone (10 mg/day), and the skin rash and systemic symptoms resolved. Schnitzler syndrome is autoinflammatory and characterized by urticarial rash and immunoglobulin M monoclonal gammopathy. Lymphoproliferative disorders feature immune dysregulation that often results in autoimmune disease (2). In patients with lymphoproliferative disorders, physicians should pay careful attention to immune complications after COVID-19 vaccination.